Editing
CUA: Surgical Management of RCC (2014)
(section)
Jump to navigation
Jump to search
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
===== '''Pretreatment prediction of tumour histology''' ===== * '''Nomograms and Classification trees have been developed and may be used to predict pretreatment histology of renal masses less than 4 cm in diameter.''' * '''Biopsy of the localized renal mass''' ** '''Biopsy of SRMs for histologic characterization is an option and may guide treatment decisions''' *** Biopsy has a mean diagnostic rate of 83%. Histology concordance is good (73-98%), Fuhrman grade concordance is not robust (32-70%) *** In the case of a non-diagnostic initial biopsy, it may be expected that a diagnosis can be made with repeat biopsy, and that the rate of malignancy remains high. *** Indeterminate initial biopsy should not be taken as reassurance regarding the malignant potential of the mass. *** It is essential to identify tumour histology in the setting of metastatic disease, both to confirm that metastatic sites represent tumour spread (and not a second primary tumour) and to classify the histologic subtype as a guide to systemic therapy. In many cases in which cytoreductive nephrectomy will have been performed, the primary histology is known and widespread metastatic disease can comfortably be assumed to be similar. If cytoreductive nephrectomy is not performed prior to planned initiation of systemic therapy, percutaneous biopsy may help to guide therapy. *** In the setting of oligometastatic disease, the link between primary and secondary masses cannot be assumed reliably. Limited data are available with regards to the role of percutaneous biopsy in this setting. ** '''Biopsy of a renal mass or metastatic site in the setting of metastatic disease is important in guiding systemic therapy.''' ** '''In patients undergoing cytoreductive nephrectomy before systemic therapy, or surgical resection of metastatic site, a biopsy may not be necessary.''' ** '''Percutaneous biopsy is associated with a low risk of complications.''' ** '''Biopsy should be reserved for patients in whom the results might change management.'''
Summary:
Please note that all contributions to UrologySchool.com may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
UrologySchool.com:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Page
Discussion
English
Views
Read
Edit
Edit source
View history
More
Search
Navigation
Main page
Clinical Tools
Guidelines
Chapters
Landmark Studies
Videos
Contribute
For Patients & Families
MediaWiki
Recent changes
Random page
Help about MediaWiki
Tools
What links here
Related changes
Special pages
Page information